Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 3/20 | 0.51 |
| ▸ | ATM | Q13315 | 14/20 | 0.45 |
| ▸ | PRKDC | P78527 | 2/20 | 0.41 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23294850 | 0.89 | FYN (0.55) | FYNATMPRKDCMTORPIK3CD | |
| SCHEMBL23339681 | 0.87 | LSS (0.48) | ATM | |
| SCHEMBL30116736 | 0.83 | ATM (0.53) | FYNATMPRKDCMTORPIK3CD | |
| SCHEMBL30116738 | 0.83 | ATM (0.53) | FYNATMPRKDCMTORPIK3CD | |
| SCHEMBL23294799 | 0.83 | ATM (0.45) | FYNATMPRKDCMTORPIK3CD | |
| SCHEMBL23294830 | 0.83 | ATM (0.43) | FYNATMPRKDCMTORPIK3CD | |
| SCHEMBL23294828 | 0.82 | HRH4 (0.45) | FYNATMPRKDCMTORPIK3CD | |
| SCHEMBL23294798 | 0.82 | FYN (0.42) | FYNATMPRKDCMTORPIK3CD | |
| SCHEMBL23294880 | 0.82 | FYN (0.43) | FYNATMPRKDCMTORPIK3CD | |
| SCHEMBL23294812 | 0.82 | ATM (0.42) | FYNATMPRKDCMTORPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11547703-B2 | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2023-01-10 | — | — | US | disclosed |
| US-20210128535-A1 | Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128535-A1 | Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof | CHEK2, CHEK1, ATM | FYN 711/4885ATM 3/4885PRKDC 83/4885 |
| US-11547703-B2 | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof | CHEK2, CHEK1, ATM | FYN 711/4885ATM 3/4885PRKDC 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.